[1] Chaly Y, Hostager B, Smith S, et al.Follistatin-like protein 1 and its role in inflammation and inflammatory di-seases[J]. Immunol Res,2014,59(1-3):266-272.
[2] Hambrock HO, Kaufmann B, Müller S, et al.Structural characterization of TSC-36/Flik: analysis of two charge isoforms[J]. J Biol Chem,2004,279(12):11727-11735.
[3] Sundaram GM, Common JE, Gopal FE, et al.'See-saw' expression of microRNA-198 and FSTL1 from a single transcript in wound healing[J]. Nature,2013,495(7439):103-106.
[4] Zwijsen A, Blockx H, van Arnhem W, et al. Characterization of a rat C6 glioma-secreted follistatin-related protein(FRP). Cloning and sequence of the human homologue[J]. Eur J Biochem,1994,225(3):937-946.
[5] Shibanuma M, Mashimo J, Mita A, et al.Cloning from a mouse osteoblastic cell line of a set of transforming-growth-factor-beta 1-regulated genes, one of which seems to encode a follistatin-related polypeptide[J]. Eur J Biochem,1993,217(1):13-19.
[6] Wei K, Serpooshan V, Hurtado C, et al.Epicardial FSTL1 reconstitution regenerates the adult mammalian heart[J]. Nature,2015,525(7570):479-485.
[7] Maruyama S, Nakamura K, Papanicolaou KN, et al.Follistatin-like 1 promotes cardiac fibroblast activation and protects the heart from rupture[J]. EMBO Mol Med,2016,8(8):949-966.
[8] Chan QK, Ngan HY, Ip PP, et al.Tumor suppressor effect of follistatin-like 1 in ovarian and endometrial carcinogenesis: a differential expression and functional analysis[J]. Carcinogenesis,2009,30(1):114-121.
[9] Sumitomo K, Kurisaki A, Yamakawa N, et al.Expression of a TGF-beta1 inducible gene, TSC-36, causes growth inhibition in human lung cancer cell lines[J]. Cancer Lett,2000,155(1):37-46.
[10] Liu S, Wang L, Wang W, et al.TSC-36/FRP inhibits vascular smooth muscle cell proliferation and migration[J]. Exp Mol Pathol,2006,80(2):132-140.
[11] Zhou X, Xiao X, Huang T, et al.Epigenetic inactivation of follistatin-like 1 mediates tumor immune evasion in nasopharyngeal carcinoma[J]. Oncotarget,2016,7(13):16433-16444.
[12] Shimano M, Ouchi N, Nakamura K, et al.Cardiac myo-cyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload[J]. Proc Natl Acad Sci U S A,2011,108(43):E899-E906.
[13] Ogura Y, Ouchi N, Ohashi K, et al.Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models[J]. Circulation,2012,126(14):1728-1738.
[14] Murakami K, Tanaka M, Usui T, et al.Follistatin-related protein/follistatin-like 1 evokes an innate immune response via CD14 and toll-like receptor 4[J]. FEBS Lett,2012,586(4):319-324.
[15] Tanaka M, Murakami K, Ozaki S, et al.DIP2 disco-interacting protein 2 homolog A (Drosophila) is a candidate receptor for follistatin-related protein/follistatin-like 1--analysis of their binding with TGF-β superfamily proteins[J]. FEBS J,2010,277(20):4278-4289.
[16] Ouchi N, Asaumi Y, Ohashi K, et al.DIP2A functions as a FSTL1 receptor[J]. J Biol Chem,2010,285(10):7127-7134.
[17] Tanaka M, Ozaki S, Kawabata D, et al.Potential preventive effects of follistatin-related protein/TSC-36 on joint destruction and antagonistic modulation of its autoantibodies in rheumatoid arthritis[J]. Int Immunol,2003,15(1):71-77.
[18] Ouchi N, Oshima Y, Ohashi K, et al.Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism[J]. J Biol Chem,2008,283(47):32802-32811.
[19] Oshima Y, Ouchi N, Sato K, et al.Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart[J]. Circulation,2008,117(24):3099-3108.
[20] Liu S, Shen H, Xu M, et al.FRP inhibits ox-LDL-induced endothelial cell apoptosis through an Akt-NF-{kappa}B-Bcl-2 pathway and inhibits endothelial cell apoptosis in an apoE-knockout mouse model[J]. Am J Physiol Endocrinol Metab,2010,299(3):E351-E363.
[21] Pachori AS, Custer L, Hansen D, et al.Bone morphogenetic protein 4 mediates myocardial ischemic injury through JNK-dependent signaling pathway[J]. J Mol Cell Cardiol,2010,48(6):1255-1265.
[22] Wu X, Li H, Kang L, et al.Activated matrix metalloproteinase-2--a potential marker of prognosis for epithelial ovarian cancer[J]. Gynecol Oncol,2002,84(1):126-134.
[23] Leroy-Dudal J, Demeilliers C, Gallet O, et al.Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2[J]. Int J Cancer,2005, 114(4):531-543.
[24] Monge M, Colas E, Doll A, et al.ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer[J]. Cancer Res,2007,67(14):6753-6759.
[25] Watakabe A, Komatsu Y, Nawa H, et al.Gene expression profiling of primate neocortex: molecular neuroanatomy of cortical areas[J]. Genes Brain Behav,2006,5(Suppl 1):38-43.
[26] Li KC, Wang F, Zhong YQ, et al.Reduction of follistatin-like 1 in primary afferent neurons contributes to neuropathic pain hypersensitivity[J]. Cell Res,2011,21(4):697-699.
[27] Lara-Pezzi E, Felkin LE, Birks EJ, et. Expression of follistatin-related genes is altered in heart failure[J]. Endocrinology,2008,149(11):5822-5827.
[28] Widera C, Horn-Wichmann R, Kempf T, et al.Circula-ting concentrations of follistatin-like 1 in healthy indivi-duals and patients with acute coronary syndrome as assessed by an immunoluminometric sandwich assay[J]. Clin Chem,2009,55(10):1794-1800.
[29] Widera C, Giannitsis E, Kempf T, et al.Identification of follistatin-like 1 by expression cloning as an activator of the growth differentiation factor 15 gene and a prognostic biomarker in acute coronary syndrome[J]. Clin Chem,2012,58(8):1233-1241.
[30] Sanchis-Gomar F, Perez-Quilis C, Lucia A.Overexpres-sing FSTL1 for Heart Repair[J]. Trends Mol Med,2016, 22(5):353-354.
[31] Fujio Y, Nguyen T, Wencker D, et al.Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart[J]. Circulation,2000,101(6):660-667.
[32] Yue TL, Wang C, Gu JL, et al.Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart[J]. Circ Res,2000,86(6):692-699.
[33] Squires CE, Escobar GP, Payne JF, et al.Altered fibroblast function following myocardial infarction[J]. J Mol Cell Cardiol,2005,39(4):699-707.
[34] Takahashi M, Okubo N, Chosa N, et al.Fibroblast growth factor-1-induced ERK1/2 signaling reciprocally regulates proliferation and smooth muscle cell differentiation of ligament-derived endothelial progenitor cell-like cells[J]. Int J Mol Med,2012,29(3):357-364.
[35] Sepe L, Ferrari MC, Cantarella C, et al.Ras activated ERK and PI3K pathways differentially affect directional movement of cultured fibroblasts[J]. Cell Physiol Biochem,2013,31(1):123-142.
[36] Shaw AK, Pickup MW, Chytil A, et al.TGFβ signaling in myeloid cells regulates mammary carcinoma cell invasion through fibroblast interactions[J]. PLoS One,2015, 10(1):e0117908.
[37] Tanaka K, Valero-Muñoz M, Wilson RM, et al.Follistatin like 1 Regulates Hypertrophy in Heart Failure with Preserved Ejection Fraction[J]. JACC Basic Transl Sci,2016, 1(4):207-221.
[38] Ikeda Y, Sato K, Pimentel DR, et al.Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction[J]. J Biol Chem,2009,284(51):35839-35849.
[39] Zhang P, Hu X, Xu X, et al.AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice[J]. Hypertension,2008,52(5):918-924.
[40] Ouchi N, Kobayashi H, Kihara S, et al.Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells[J]. J Biol Chem,2004,279(2):1304-1309.
[41] Kempf T, Wollert KC.Nitric oxide and the enigma of cardiac hypertrophy[J]. Bioessays,2004,26(6):608-615.
[42] El-Armouche A, Ouchi N, Tanaka K, et al.Follistatin-like 1 in chronic systolic heart failure: a marker of left ventricular remodeling[J]. Circ Heart Fail,2011,4(5):621-627.
[43] Kempf T1, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury[J]. Circ Res,2006,98(3):351-360.
[44] Wollert KC, Kempf T, Peter T, et al.Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome[J]. Circulation,2007, 115(8):962-971.
